Ionis Pharmaceuticals, Inc.
IONS
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipā¦ read more
Healthcare
Biotechnology
34 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$63.96
Price+1.57%
$0.99
1Y
Price
Market Cap
$10.194b
Large
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years+33.2%
EBITDA Margin+27.3%
Net Profit Margin-36.1%
Free Cash Flow MarginRevenue
$944.237m
+33.9%
1y CAGR+19.2%
3y CAGR+7.5%
5y CAGREarnings
-$268.216m
+40.9%
1y CAGR-6.2%
3y CAGR-212.4%
5y CAGREPS
-$1.84
+39.5%
1y CAGR-4.7%
3y CAGR-204.7%
5y CAGRBook Value
$631.724m
$2.985b
Assets$2.353b
Liabilities$1.420b
DebtDebt to Assets
47.6%
-7.5x
Debt to EBITDAFree Cash Flow
-$569.175m
-4.2%
1y CAGR-27.0%
3y CAGR-616.0%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company